Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
Holding AVBP?
Track your performance easily
AVBP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.35 - $36.37
Previous Close$27.41
Volume187.13K
Average Volume (3M)283.61K
Market Cap
$923.98M
Enterprise Value$641.33M
Total Cash (Recent Filing)$282.86M
Total Debt (Recent Filing)$213.00K
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Mar 27, 2025EPS Estimate
-$0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.42
Shares Outstanding33,697,161
10 Day Avg. Volume170,399
30 Day Avg. Volume283,607
Standard Deviation0.16
R-Squared0.00054
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)3.12
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-15.11
Forecast
1Y Price Target
$37.25Price Target Upside40.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
ArriVent BioPharma, Inc. News
PremiumCompany Announcements
ArriVent BioPharma Advances Cancer Therapeutics Pipeline
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsFirmonertinib demonstrated a best overall response rate of 81.8% at the 240 mg daily dose, including all unconfirmed responses, showcasing its promising efficacy in EGFR PACC NSCLC.
Financial PositionArriVent ended 3Q24 with $282.9M in cash, cash equivalents, and marketable securities, which should provide an operational runway into 2026 and through multiple clinical data readouts.
Market PotentialThere is no FDA approved agent for NSCLC patients with EGFR PACC mutations and no broadly utilized standard of care treatment, highlighting a significant opportunity for firmonertinib to address an unmet need.
Bears Say
Clinical TrialsRisks include slower than anticipated enrollment in the Phase 3 FURVENT trial and negative efficacy data from the FURVENT trial.
Investor SentimentShort interest is at 18.3% of float, indicating significant skepticism among investors.
Regulatory ChallengesIt is unclear on the clinical path forward for firmonertinib as it relates to whether a registrational, single-arm trial will be enough for approval, or whether a randomized controlled study will be needed.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $14.35 and its highest was $36.37 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
Currently, no data Available
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is Mar 27, 2025 which is in 125 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Nov 14, 2024. The company reported -$0.61 earnings per share for the quarter, beating the consensus estimate of -$1.003 by $0.393.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -$0.8.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 33,697,163 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.61 in its last earnings report, beating expectations of -$1.003. Following the earnings report the stock price went down -11.864%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Among the largest hedge funds holding ArriVent BioPharma, Inc.’s share is Perceptive Advisors LLC. It holds ArriVent BioPharma, Inc.’s shares valued at 10M.
---
ArriVent BioPharma, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.25 (40.09% Upside)
$37.25 (40.09% Upside)
Hedge Fund Trend
Increased
By 20.9K Shares
Last Quarter.
Last Quarter.
Fundamentals
Return on Equity
-36.06%
Trailing 12-Months
Asset Growth
60.75%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc.
---
AVBP Stock 12 Month Forecast
Average Price Target
$37.25
▲(40.09% Upside)
Technical Analysis
Best Analysts Covering AVBP
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+35.60%
assigned a buy rating 3 months ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +35.60% per trade.
---